For people who haven't responded well to medication, or who specifically want to avoid it, TMS offers something genuinely different in psychiatric and addiction treatment: a non-drug, non-invasive approach that works by directly stimulating specific brain regions with magnetic pulses. It's been FDA-approved for depression for over a decade and, more recently, for smoking cessation, with growing research interest in its potential for other substance use disorders. Here's how it actually works and what the evidence currently supports.
Transcranial magnetic stimulation uses a magnetic coil placed against the scalp to generate targeted magnetic pulses that pass through the skull and stimulate activity in specific, precisely located brain regions. Unlike electroconvulsive therapy, TMS doesn't require anesthesia, doesn't cause seizures as part of its intended mechanism, and doesn't cause memory loss, patients remain fully awake and alert throughout each session and can drive themselves home afterward.
A typical treatment course involves daily sessions, five days a week, over four to six weeks, with each session lasting roughly 20 to 40 minutes depending on the specific protocol used. This is a genuine time commitment, though newer accelerated protocols, delivering multiple sessions per day over a shorter overall course, have shown promise in reducing the total treatment timeline.
Depression and addiction are both associated with altered activity in specific brain regions, particularly the prefrontal cortex, an area involved in mood regulation, decision-making, and impulse control. In depression, activity in the left dorsolateral prefrontal cortex is often reduced; in addiction, brain imaging studies have found altered activity in prefrontal regions involved in craving and impulse control specifically. TMS is designed to stimulate these underactive regions directly, using precisely targeted magnetic pulses, in an effort to normalize activity and, over a course of treatment, produce lasting changes in how these circuits function.
| Condition | FDA Status |
|---|
| Major depressive disorder | FDA-approved since 2008, specifically for treatment-resistant depression that hasn't responded adequately to medication |
| Obsessive-compulsive disorder | FDA-approved as an adjunct treatment |
| Smoking cessation | FDA-cleared in 2020, using a specific protocol targeting brain regions associated with nicotine craving |
| Other substance use disorders | Not yet FDA-approved specifically; an active area of ongoing clinical research |
The FDA clearance for smoking cessation was based on a multi-site clinical trial that found a specific TMS protocol, targeting the prefrontal cortex and insula, a brain region involved in craving and interoception, produced meaningfully higher smoking cessation rates compared to a sham (placebo) treatment. This remains the clearest, most established evidence for TMS in addiction treatment specifically, since it's the only substance use application to receive formal FDA approval to date.
Beyond smoking, research into TMS for other substance use disorders is genuinely promising but earlier-stage, without the same level of formal approval:
- Alcohol use disorder. Several controlled studies have found TMS associated with reduced craving and, in some trials, reduced drinking, though the overall body of research remains smaller than for smoking cessation specifically.
- Cocaine use disorder. Early trials have reported reduced craving and some reduction in use following TMS treatment, an encouraging signal given the absence of FDA-approved medication for cocaine use disorder specifically, discussed further in our contingency management guide, which covers another approach used for this same treatment gap.
- Opioid use disorder. A smaller number of studies have examined TMS as a complement to standard treatment, generally focused on craving reduction rather than as a standalone approach to opioid use disorder.
Across these areas, researchers are still working out optimal targeting protocols, session frequency, and which patients are most likely to benefit, meaning TMS for substance use disorders beyond nicotine should currently be understood as a promising complementary approach under active investigation, not an established, first-line treatment.
Given how frequently depression and substance use disorders co-occur, a topic covered in more depth in our dual diagnosis guide, TMS's established effectiveness for treatment-resistant depression makes it a particularly relevant option for people whose depression hasn't responded to medication and who are also navigating a substance use disorder. Treating the depression component effectively can meaningfully support the addiction treatment process, since untreated depression is a well-documented relapse risk factor.
- Initial evaluation, including a review of medical history to rule out contraindications, particularly metal implants near the head, a history of seizures, or certain other neurological conditions
- Mapping session, where the treatment team identifies the precise stimulation location and determines the appropriate intensity for that individual
- Daily treatment sessions, typically five days a week over four to six weeks, though accelerated protocols compressing this timeline are increasingly available
- Progress monitoring throughout the course, with standardized symptom measures tracked to assess whether the expected improvement is occurring
- Maintenance planning, since some patients benefit from periodic follow-up sessions after the initial course to sustain improvement over time
Most patients describe a tapping or knocking sensation on the scalp during treatment, sometimes mildly uncomfortable, particularly during the first few sessions, but generally well tolerated. Common side effects are mild and include scalp discomfort at the treatment site and headache, both typically resolving shortly after each session. A more serious but rare risk is seizure, occurring in a very small fraction of treatments, which is why careful screening for seizure risk factors is a standard part of the evaluation process before beginning treatment.
- People with certain metal implants or devices near the head, including some pacemakers, cochlear implants, or metallic fragments, due to the magnetic field involved
- People with a history of seizures or certain seizure-risk conditions, without careful specialist evaluation first
- People seeking a standalone treatment for a substance use disorder beyond nicotine, given that formal approval doesn't yet extend there; TMS in this context should be considered a complement to established treatment, not a replacement for it
TMS for treatment-resistant depression is covered by many insurance plans, though prior authorization is often required, typically involving documentation that standard treatments, medication and therapy, have already been tried without adequate success. Coverage for TMS specifically for smoking cessation or other substance use applications is less consistent and worth confirming directly with a specific insurer and treatment provider before starting.
For depression specifically, where TMS has the longest track record, it's generally positioned as an option for people who haven't responded adequately to at least one, and often several, medication trials, rather than as a first-line alternative to medication for everyone. This reflects both the practical realities of treatment access, TMS requires daily visits over several weeks, which is a bigger time commitment than taking a daily pill, and the research base, which has focused specifically on treatment-resistant cases. That said, TMS carries a meaningfully different side effect profile than most antidepressant medications: no weight changes, no sexual side effects, no drug interactions to manage, which makes it an appealing option for people who've discontinued medication specifically because of these effects rather than because the medication wasn't working.
For addiction treatment specifically, TMS isn't positioned as a replacement for medication-assisted treatment where MAT is already established and effective, such as buprenorphine or methadone for opioid use disorder. Instead, it's more accurately understood as an additional tool, particularly relevant for the substances and situations where medication options are limited or absent, such as cocaine and methamphetamine use disorder, or as a complement addressing co-occurring depression that medication alone hasn't resolved.
One of the more significant recent developments in the field has been the emergence of accelerated TMS protocols, delivering multiple treatment sessions in a single day rather than one session daily over several weeks. Research on these compressed protocols, sometimes completing a full course in as little as five days, has found comparable effectiveness to the traditional six-week schedule in several studies, a meaningful development for anyone for whom a six-week daily commitment isn't practically feasible. This approach is still becoming more widely available and isn't offered at every TMS provider, so it's worth asking directly whether a specific accelerated option exists if the standard schedule presents a genuine barrier to starting treatment.
TMS represents a genuinely different treatment mechanism than medication or talk therapy, working directly on brain circuit activity rather than through pharmacology or behavioral intervention alone. Its evidence base is strongest and most established for depression and, within addiction treatment specifically, for smoking cessation. For other substance use disorders, it's a promising, actively researched complementary approach rather than an established standalone treatment, and it's most reasonably considered as part of a broader treatment plan, particularly for people whose co-occurring depression hasn't responded well to other approaches.
You can browse our directory of programs offering TMS to find facilities with this treatment available.
Frequently asked questions
It's FDA-cleared specifically for smoking cessation. For other substance use disorders, including alcohol, cocaine, and opioid use disorder, it remains under active clinical research without formal FDA approval for those specific applications yet.
No, patients remain fully awake and alert throughout each session and can resume normal activities, including driving, immediately afterward.
TMS doesn't require anesthesia, doesn't intentionally induce a seizure as part of treatment, and doesn't cause the memory effects sometimes associated with ECT. The two are distinct treatments with different mechanisms, despite occasional public confusion between them.
A standard course involves daily sessions, five days a week, over four to six weeks, though accelerated protocols delivering multiple sessions per day over a shorter overall period are increasingly available.
The most common side effects are mild scalp discomfort and headache during or shortly after treatment. Seizure is a rare but serious potential risk, which is why careful screening for seizure risk factors is part of the standard evaluation before treatment begins.
Coverage for TMS in treatment-resistant depression is fairly well established with many insurers, generally requiring documentation that standard treatments were tried first. Coverage specifically for smoking cessation or other substance use applications is less consistent and worth confirming directly with your insurer.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: September 2026
Related articles
Resources
